Cardio3 BioSciences Grosses $30M in Brussels, Paris IPO
Shares in Cardio3 Biosciences SA performed strongly on their first day of trading, following a July 4 initial public offering (IPO) on the NYSE Euronext exchanges in Brussels and Paris that raised €23 million (US$29.6 million).
The Mont-Saint-Guibert, Belgium-based stem cell therapy developer priced the offering at €16.65 per share, at the bottom of the indicative price range of €16.65 to €19 per share it set in advance of the book-building process.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter